2-(5-Methylisoxazol-3-yl)but-3-yn-2-ol → (+/-)-10-(3-Hydroxy-3-(5-methylisoxazol-3-yl)but-1-yn-1-yl)-6-(hydroxymethyl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide
Reaktionsgleichung
Br[C:2]1[CH:3]=[CH:4][C:5]2[O:11][CH:10]([CH2:12][OH:13])[CH2:9][N:8]3[CH:14]=[C:15]([C:17]([NH2:19])=[O:18])[N:16]=[C:7]3[C:6]=2[CH:20]=1.[CH3:21][C:22]1[O:26][N:25]=[C:24]([C:27]([OH:31])([C:29]#[CH:30])[CH3:28])[CH:23]=1>>[OH:31][C:27]([C:24]1[CH:23]=[C:22]([CH3:21])[O:26][N:25]=1)([CH3:28])[C:29]#[C:30][C:2]1[CH:3]=[CH:4][C:5]2[O:11][CH:10]([CH2:12][OH:13])[CH2:9][N:8]3[CH:14]=[C:15]([C:17]([NH2:19])=[O:18])[N:16]=[C:7]3[C:6]=2[CH:20]=1Komponenten
3
Edukt 2
Produkt 1
Versuchsvorschrift
Similar to as described in General Procedure G, racemic 10-bromo-6-(hydroxymethyl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide was reacted with racemic 2-(5-methyl-1,2-oxazol-3-yl)but-3-yn-2-ol to give the titled compound as a yellow solid (mixture of diasteromers, 98 mg, 40%).